COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs

Objectives We aimed to investigate the role of rheumatoid arthritis (RA) with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) exposure in COVID-19 outcomes.Methods Our study retrieved data from the US Collaborative Network in TriNetX between 1 January 2018 and 31 Dec...

Full description

Bibliographic Details
Main Authors:	James Cheng-Chung Wei, Jih-Jin Tsai, Li-Teh Liu, Chun-Hong Chen, Liang-Jen Chen, Shiow-Ing Wang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-07-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/9/3/e003038.full

Similar Items

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
by: Maria Kalweit, et al.
Published: (2023-06-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023-05-01)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
by: Ju-Yang Jung, et al.
Published: (2023-09-01)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
by: Laura C. Cappelli, et al.
Published: (2023-10-01)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
by: Susan Siyu Wang, et al.
Published: (2023-07-01)

CORRELATIONS BETWEEN SYSTEMIC THERAPY WITH CONVENTIONAL (SYNTHETIC) AND BIOLOGICAL DMARDS, RHEUMATOID ARTHRITIS AND PERIODONTAL INDICES OF CHRONIC PERIODONTITIS
by: Maria Alexandra Martu, et al.
Published: (2019-01-01)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
by: Tillett, W, et al.
Published: (2020)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
by: Edwards, C, et al.
Published: (2008)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
by: Hazan Karadeniz, et al.
Published: (2022-04-01)

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
by: Jobanputra, P, et al.
Published: (2004)

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
by: Tucker, L, et al.
Published: (2022)

Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis
by: Jin-Won Kwon, et al.
Published: (2024-04-01)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
by: Merete Lund Hetland, et al.
Published: (2022-12-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
by: Maria Sergeevna Voronina, et al.
Published: (2012-10-01)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
by: Giovanni Adami, et al.
Published: (2023-01-01)

Complementary Therapies and Their Association with Problems in Therapeutic Adherence to Conventional Synthetic DMARDs in Rheumatoid Arthritis: A Cross-Sectional Study
by: Aline Priscilla Santiago-Garcia, et al.
Published: (2023-12-01)

Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis
by: Maria Sofia Ciliento, et al.
Published: (2023-03-01)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
by: Edwards, C, et al.
Published: (2005)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
by: Emiliano Marasco, et al.
Published: (2023-09-01)

Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study
by: Mattia Bellan, et al.
Published: (2022-05-01)

Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
by: Williams, R, et al.
Published: (1999)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
by: Juan M. Reyes, et al.
Published: (2023-03-01)

Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs)
by: Giovanni Adami, et al.
Published: (2023-09-01)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
by: Min Shi, et al.
Published: (2023-10-01)

Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs
by: Kei Ikeda, et al.
Published: (2024-02-01)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
by: Esteban A. Gomez, et al.
Published: (2020-10-01)

Effectiveness and safety of 99Tc-methylene diphosphonate as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional synthetic (cs) DMARDs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 34 randomized controlled trials
by: Guoqian Deng, et al.
Published: (2023-11-01)

Targeting MyD88 Downregulates Inflammatory Mediators and Pathogenic Processes in PBMC From DMARDs-Naïve Rheumatoid Arthritis Patients
by: Sergio Ramirez-Perez, et al.
Published: (2021-12-01)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022-08-01)

Trends of adverse events and mortality after DMARDs in patients with rheumatoid arthritis: Interrupted time‐series analysis
by: Yao‐Fan Fang, et al.
Published: (2022-07-01)

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
by: Carl K Edwards, et al.
Published: (2012-12-01)

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
by: Coates, LC, et al.
Published: (2016)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
by: Marie Kostine, et al.
Published: (2022-10-01)

How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study
by: Issrah I. Jawad, et al.
Published: (2022-04-01)

The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis
by: Der-Yuan Chen, et al.
Published: (2022-12-01)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
by: Coates, L, et al.
Published: (2017)

Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients
by: Jorge Monserrat Sanz, et al.
Published: (2020-09-01)

Incidence of knee and hip replacements in rheumatoid arthritis patients following introduction of biological dmards: an interrupted time series analysis using nationwide health care registers
by: Cordtz, R, et al.
Published: (2017)

Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers
by: Cordtz, R, et al.
Published: (2017)